Express™ SD Renal and Biliary Premounted Stent System

Name: Express™ SD Renal and Biliary Premounted Stent System - Boston Scientific
Brand: Boston Scientific

The Express SD Stent couples excellent compression resistance with lower stent foreshortening and recoil. Only Express SD has the ideal balance of strength and precision for acute success.

Explore product details

Reimbursement

Coding and payment guides

Configure or select a product to continue to order

Instructions for use are found inside the product packaging and on our product literature website.

Access product literature

Need additional help with product literature?

Go to customer support

Overview
Clinical Data
Training
Resources

Excellence in compression resistance

The Express SD Stent couples excellent compression resistance with lower stent foreshortening and recoil. Only Express SD has the ideal balance of strength and precision for acute success.

How it works

Express SD features a patented Tandem Architecture™ Stent Design

Macro™ Elements and additional proximal connectors engineered to provide strength, especially in ostial lesions
Micro™ Elements designed to provide flexibility during stent placement

Why choose Express SD

Express™ SD Renal and Biliary Premounted Stent System Compression Resistance bench test results.

Best-in-class compression resistance

Compression Resistance defined as the force required to compress the fully expanded stent. Compression Resistance measured using the hoop force tester in 37° C air. Bench testing performed by Boston Scientific Corporation. Data on file. N=3. Express SD, RX Herculink Plus, Herculink Elite, PALMAZ Blue and Racer stents tested: 6 x 18 mm. Formula 418 RX tested: 6 x 20mm. Bench test results may not necessarily be indicative of clinical performance.

Express™ SD Renal and Biliary Premounted Stent System Foreshortening bench test results.

Minimal foreshortening

Foreshortening defined as the change in stent length from crimped conditions to nominally expanded condition in 37° C water, as measured by a magnified vision system. Bench testing performed by Boston Scientific Corporation. Data on file. N=3. Express SD, RX Herculink Plus, Herculink Elite, PALMAZ Blue and Racer stents tested: 6 x 18 mm. Formula 418 RX tested: 6 x 20mm. Bench test results may not necessarily be indicative of clinical performance.

Very low recoil

Stent Recoil defined as the change in stent diameter from nominally pressurized catheter to non-pressurized catheter condition in 37° C water, as measured by a magnified vision system. Bench testing performed by Boston Scientific Corporation. Data on file. N=3. Express SD, RX Herculink Plus, Herculink Elite, PALMAZ Blue and Racer stents tested: 6 x 18 mm. Formula 418 RX tested: 6 x 20mm. Bench test results may not necessarily be indicative of clinical performance.

Featured clinical data

RENAISSANCE Clinical Trial

Overview

The RENAISSANCE Trial was a prospective, multi-center, single arm study designed to evaluate the Express SD Renal Premounted Stent System in the treatment of atherosclerotic lesions in the aortorenal ostium.

The primary objective was to demonstrate superiority of the duplex triggered, angiographically-confirmed binary restenosis rate at 9-months over the 40% pre-specified Objective Performance Criterion (OPC) representative of PTRA.

Trial Design

The RENAISSANCE Trial enrolled 100 patients (117 lesions) with de novo or restenotic ostial atherosclerotic lesions ≤15mm long in vessels between 4.0 and 7.0mm diameter with diameter stenosis ≥70%.

Outcomes

Primary Endpoint: 21.3% binary in-stent restenosis rate at 9-months, defined as the proportion of target lesions with ≥50% diameter stenosis based on angiographic core lab assessment.

5-Year Data

RENAISSANCE Clinical Trial chart of Freedom from Target Lesion Revascularization to 5-Years Follow-Up (1855 days).

RENAISSANCE Clinical Trial chart of Blood Pressure .

RENAISSANCE Clinical Trial chart of Number of Anti-Hypertensives.

Additional results

Additional RENAISSANCE Clinical Trial results.

References:
*Denominator consists of number of subjects who either died prior to late follow-up window and/or had follow-up to at least the early follow-up window.

**Denominator consists of number of subjects who either had CEC adjudicated device or procedure related death prior to late follow-up window and/or had follow-up to at least the early follow-up window.

†Matched data by time point.

For additional information, please see Rocha-Singh K, Jaff M, Kelley E.L. Renal Artery Stenting with Non-Invasive Duplex Ultrasound Follow-up: 3-Year Results from the RENAISSANCE Renal Stent Trial. Catheterization and Cardiovascular Interventions 2008; 72:853-862.

Online medical training and education courses

The EDUCARE online platform makes healthcare education and training more relevant, more comprehensive, more personal, and more accessible. Register to access a library of procedural videos, case studies, training resources, and events.

On demand

Get 24-hour access to content from your desktop, laptop, or mobile device.

Personalized

Explore interactive videos, case studies, and more, tailored to your medical field.

Trusted

Gain education and insights from globally recognized industry experts.

Resources list

PI Product Catalog

Express is a registered or unregistered trademark of Boston Scientific Corporation or its affiliates. All other trademarks are the property of their respective owners.

My account